Skip to content
10-K

Annual Report

BridgeBio Oncology Therapeutics, Inc. BBOT

0001193125-26-094112

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 80.03M sh
Shares Diluted FY 2025 · Dec 31, 2025 31.14M sh
Shares Diluted FY 2025 · Dec 31, 2024 12.9K sh
Capex FY 2025 · Dec 31, 2025 $606K
Capex FY 2025 · Dec 31, 2024 $49K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$113.89M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$55.03M
Cash And Equivalents FY 2025 · Dec 31, 2025 $373.69M
Cash And Equivalents FY 2025 · Dec 31, 2024 $30.85M
Stockholders Equity FY 2025 · Dec 31, 2025 $411.1M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$178.64M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$115.64M
Current Liabilities FY 2025 · Dec 31, 2025 $35.04M
Current Liabilities restated FY 2025 · Dec 31, 2024 $19.58M
Total Liabilities FY 2025 · Dec 31, 2025 $37.29M
Total Liabilities restated FY 2025 · Dec 31, 2024 $19.58M
Current Assets FY 2025 · Dec 31, 2025 $432.4M
Current Assets restated FY 2025 · Dec 31, 2024 $158.69M
Total Assets FY 2025 · Dec 31, 2025 $448.38M
Total Assets restated FY 2025 · Dec 31, 2024 $164.3M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.30
Eps Diluted FY 2025 · Dec 31, 2024 −$5,756.41
Eps Basic FY 2025 · Dec 31, 2025 −$4.30
Eps Basic FY 2025 · Dec 31, 2024 −$5,756.41
Sga Expense FY 2025 · Dec 31, 2025 $24.62M
Sga Expense restated FY 2025 · Dec 31, 2024 $7.76M
Rd Expense FY 2025 · Dec 31, 2025 $121.2M
Rd Expense FY 2025 · Dec 31, 2024 $73.11M
Net Income FY 2025 · Dec 31, 2025 −$134.04M
Net Income restated FY 2025 · Dec 31, 2024 −$74.28M
Operating Income FY 2025 · Dec 31, 2025 −$145.82M
Operating Income restated FY 2025 · Dec 31, 2024 −$80.86M